Table 1.
Summary of included studies and participants’ characteristics
| Reference | Country | Study Design | Number of Subjects (n) | Age of subjects (years) | Cancer Type |
|---|---|---|---|---|---|
| (35) | USA | Cross sectional Using questionnaire (person, disease and work related factors) | n=250 Men: 46.5% Women: 53.5% | 30-59 | Colorectal |
| (29) | Korea | Cross sectional with reference group Using questionnaire (employment status, demographic data and clinical variables) | n=1594 Women |
20-60 | Breast |
| (34) | UK | Cross sectional Using Brief Illness Perceptions Questionnaire (perceived impact of cancer and its treatment on work) | n=194 Men (40%) Women (60%) |
51 | Breast Urological Gynaecological Head and Neck |
| (25) | France | Cross sectional Using questionnaire (on personal, disease-related and occupational characteristics) | n=379 Women | 18-60 | Breast |
| (26) | USA | Longitudinal Using telephone interview (12 and 18 months post diagnosis) | n=416 Women |
30-64 | Breast |
| (20) | Korea | Longitudinal Prospective Cohort Using employment questionnaire (every 3 months for 24 months) | n=305 Men | ≥18 | Stomach (32%) Liver (38%) Colorectal (30%) |
| (9) | Australia | Population-based longitudinal Using telephone survey | n= 975 Men: 64% Women: 36% | 20-80 | Colorectal |
| (39) | Netherlands | Longitudinal Follow up | n=195 Men:40% Women:60% | 18-58 | Breast (26%) Haematological (12%) Gastrointestinal (12%) Female genitals (22%) Genitourinary (22%) Others (6%) |
| (30) | Canada | Longitudinal Telephone interview (4 and 15 months after diagnosis) | n: 2422 Men: 53% Women: 47% | ≥21 | Lung (34%) Colorectal (66%) (Non-metastatic) |
| (21) | Sweden | Randomised trial (Follow up for 24 months) | n=222 Women |
29-54 | Breast |
| (31) | Sweden | Qualitative: In-depth interview, Retrospective narration |
n=16 -recurrent-free women -50% women RTW -50% women not yet RTW |
44- 58 | Breast |
| (23) | UK | Qualitative: Individual interview (n=19) Focus group (n=4, n=6) | n=29 Women:93% Men: 7% | 52.6 N |
Breast (83%), on-Hodgkin’s lymphoma (7%), Uterus (7%) Larynx (3%) |
| (12) | USA | Qualitative: Focus group | n=7 women | 18-55 | Breast (57%) Lung (14%) Acute Myeloid Leukemia (14%) Ovarian cancer (14%) |
| (24) | USA | Qualitative, Face to face structured interview | n=28 Men: 50%; Women:50% |
24-63 | Gastrointestinal (17.9%) Brain (10.7%) Leukemia/ Lymphoma (10.7%) Lung (10.7%) Thyroid (10.7%) Breast (7.1%) Urinary tract (bladder) (7.1%) Male genital tract (7.1%) Skin (7.1%) Head and neck (7.1%) Female genital tract (3.6%) |
| (38) | UK | Qualitative, Telephone interview | n=26 Men:38% Women:62% | 31-61 | Breast (35%) Prostate (15%) Lymphoma (12%) Ovaries (12%) Oesophageal (4%) Renal (4%) Bladder (4%) Brain tumour (4%) Colon (4%) Thyroid (4%) Pancreatic (4%) |
| (28) | Netherlands | Longitudinal study (sickness absence and full RTW after 2yrs post diagnosis) | n=5074 Men: 35.5% Women: 64.5% | 18-60 | Breast (31.1%) Female genitals (16.9%) Gastro-intestinal (14.2%) Lung (8.8%) Male genitals (8%) Skin (6%) Blood (5.8%) Other (9.12%) |
| (37) | Netherlands | Longitudinal study | n=5234 Men: 36% Women: 64% | 18-60 | Breast (31.1%) Female genitals (16.9%) Gastro-intestinal (14.2%) Lung (8.8%) Male genitals (8%) Skin (6%) Blood (5.8%) Other (9.12%) |
| (36) | Sweden | Qualitative Focus group (x4) | n=23 Women |
20-63 | Breast |
| (33) | Belgium | Qualitative In-depth interview | n=22 Women | 42-55 | Breast |
| (32) | UK | Qualitative Semi-structured interview | n=50 Men | 18-65 | Prostate |
| (17) | Germany | Longitudinal Follow up at end of rehabilitation, t1(3weeks) and t2(12 months after rehabilitation) | n=750 Men:14.3% Women: 85.7% | 18-60 | Breast (59.5%) Gynaecological (14.5%) Head and neck cancer (8.9%) Skin (6.1%) Colorectal (5.6%) Lung (3.1%) Haematological (2.3%) |
| (27) | Denmark | Cross-sectional | n=1490 Men: 36% Women: 64% |
18-80 | Breast (37%) Gastro (8%) Lung (3%) Gynaec (12%) Prostate (3%) Urinary (2%) Head and neck (4%) Lymphoma (12%) Leukaemia (6%) Other (15%) |
| (49) | USA | Cross-sectional with reference group | Cancer survivors, n=100 Non cancer, n=103 |
45 | Breast |
| (50) | Finland | Cross-sectional with reference group | Cancer survivors, n=591 Women:74% Men:26% |
25-57 | Women Breast cancer (90%) Lymphoma (10%) Men Lymphoma (41%) Prostate (30%) Testicular (29%) |
| (51) | Korea | Cross-sectional with reference group | Cancer survivors n=408 General population n=994 |
18-65 | Stomach cancer |
| (22) | USA | Population-based longitudinal | Cancer survivors n=4991 General population n=1334 |
25-55 | Oral (2.1%) Stomach (26.3%) Colorectal (11.7%) Liver (16.3%) Pancreas (2.3%) Lung (8.4%) Breast (8.3%) Cervix and uterus (3.7%) Kidney (3.3%) Bladder (2.4%) Brain & CNS (3.1%) Thyroid (7.0%) Non Hodgkin’s (2.3%) Leukemia (2.7%) |
| (52) | USA | Cross-sectional with reference | Cancer survivors n=7531 Men: 47% Women: 53% | 55-64 | Mixed |